Press Room

Event

ASD-HIPROS Learning Lab

Start
Thursday, July 29, 2021 - 00:00
End
Thursday, August 12, 2021 - 00:00
Location: online
Schedule meeting with Hovione ASD-HIPROS Learning Lab | Hovione

Join our exclusive Learning Lab at CPhI North America

“ASD-HIPROS - A new platform for quick and effective 
formulation screening for Amorphous Solid Dispersions by Spray Drying”

 

Join our expert. In just 20 minutes you will learn:

  1. Introduction to Hovione’s new formulation screening platform by Spray Drying
  2. Learn about the advantages of a platform that integrates in silico computational models, formulation, analytical development
  3. Get to know more about Hovione’s extensive expertise in Spray Drying

 

REGISTER NOW

 

Synopsis

The number of drug candidates that present low solubility issues has been increasing over the past years. Amorphous Solid Dispersions (ASDs) are an established platform to address bioavailability challenges of poorly soluble drug candidates, offering many of the advantages of more conventional solid oral dosage forms while providing faster dissolution rates and higher drug concentrations. Suboptimal formulations of poorly soluble compounds may result in clinical failures, ultimately increasing the development timeline and associated costs towards identifying a winning candidate. Register now!

 

Targeted at APIs with poor solubility issues, ASD-HIPROS, Hovione’s Intelligent Proprietary Screening, is a methodology able to evaluate if formulations by Spray Drying are viable candidates towards solving poor bioavailability issues. Equipped with a computational platform coupled with state-of-the-art analytical and spray drying technologies, this platform is able to deliver optimal formulations in record time with minimal consumption of API, maximizing the chance of identifying a successful formulation and accelerating development towards clinical supplies.

 

Who should attend:

  1. Formulators
  2. Scientists
  3. Investigators and Research fellows
  4. R&D personnel
  5. Technical services personnel

 

REGISTER NOW

 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping
Contract Pharma, 24 September 2025

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

Also in Events

See All